For decades, some cancers were a near-certain death sentence. Now, a new generation of cancer drugs—many coming from biotech, not big pharma—is changing that. RTW’s Chris Liu discusses ASCO 2026, and breakthroughs in pancreatic cancer, lung cancer, and other hard-to-treat tumors. What's driving the progress, why is it happening now, and what does it mean for the future of cancer care?
PODCAST TEAM
Producer & Director: Devon Leaver
Editor: Dominique Guerra
Production Coordinator: Ying Yu Lin
Production Support: Annabelle Chan
Production Assistant: Nicole M. Rosales
Executive Editorial Advisor: Stephanie A. Sirota
Research Consultant: Chris Liu
Research Consultant: Julia Harper
Research Consultant: Lauren Lee
Theme Music: Yehezkel Raz
Additional Music: APM Music
Featuring by Chris Liu, Senior Research Analyst, moderated by Stephanie Sirota, Partner, and Chief Business Officer at RTW Investments.
FOLLOW US
Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.
To make sure you never miss an episode, you can subscribe to the RTW podcast on YouTube, Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.
CHAPTERS
00:00 - Introduction
1:04 – The Evolution of Cancer Treatments
3:19 - Unmet Needs in Oncology
10:03 - Treating Pancreatic Cancer
14:20 - The Importance of ASCO
16:48 - The Rise of Chinese Biotech
21:54 - Trends in Oncology
23:42 - Outro
DISCLAIMER
This interview was given by Chris Liu, Senior Research Analyst, and moderated by Partner, and Chief Business Officer Stephanie Sirota, at RTW Investments. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own and their appearance on the program does not imply an endorsement of them or any entity they represent.
